Current research into retatrutide, a dual agonist for GLP-1 and GIP receptors, are demonstrating significant results in managing obesity and type second-type disease. Preclinical data suggest a distinct mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/